<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PHENTERMINE RESINÂ ER- phentermineÂ capsule, extended releaseÂ </strong><br>Lannett Company, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use <span class="Bold">phentermine resin extended-release capsules</span> safely and effectively. See full prescribing information for <span class="Bold">phentermine resin extended-release capsules</span>.</span><br><br><span class="Bold"><span class="Bold">PHENTERMINE Resin Extended-Release Capsules</span> CIV</span><br><span class="Bold">Initial U.S. Approval: 1959</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Phentermine resin extended-release capsules are a sympathomimetic amine <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> for patients with an initial body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index â‰¥ 30 kg/m2, or â‰¥ 27 kg/m<span class="Sup">2</span> in the presence of other risk factors (e.g., controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>). (<a href="#LINK_cefde348-0fb1-4093-b556-4340f81f8038">1</a>) </p>
<p class="Highlighta">The limited usefulness of agents of this class, including phentermine, should be measured against possible risk factors inherent in their use. (<a href="#LINK_cefde348-0fb1-4093-b556-4340f81f8038">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li>Dosage should be individualized to obtain an adequate response with the lowest effective dose. (<a href="#LINK_3b285d95-0e26-4926-8692-bf75a350b483">2</a>) 
</li>
<li>One capsule daily, before breakfast or 10-14 hours before retiring. (<a href="#LINK_3b285d95-0e26-4926-8692-bf75a350b483">2</a>) 
</li>
<li>Late evening administration should be avoided (risk of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>). (<a href="#LINK_3b285d95-0e26-4926-8692-bf75a350b483">2</a>)
</li>
<li>Phentermine resin extended-release capsules can be taken with or without food (<a href="#LINK_60cdc50a-f929-400e-8f7e-a1402695cc88">12.3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk"><li>Capsules containing cationic resin complex equivalent to 15 mg or 30 mg phentermine base.</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disk">
<li>History of cardiovascular disease (e.g., <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>) (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>)
</li>
<li>During or within 14 days following the administration of monoamine oxidase inhibitors (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span> (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> states (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>)
</li>
<li>History of drug abuse (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>)
</li>
<li>Pregnancy (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>, <a href="#LINK_6d464131-5469-4ec2-b81a-7aed93eb0059">8.1</a>)
</li>
<li>Nursing (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>, <a href="#LINK_04233cef-65a8-45aa-bc31-b0b1be558456">8.3</a>)
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, or idiosyncrasy to the sympathomimetic amines (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Coadministration with other drugs for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> is not recommended (safety and efficacy of combination not established). (<a href="#LINK_0d8b1c7d-ac0d-4d15-9645-6889ba4b77cb">5.1</a>) 
</li>
<li>Rare cases of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">primary pulmonary hypertension</span> have been reported. Phentermine should be discontinued in case of new, unexplained symptoms of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or lower extremity <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. (<a href="#LINK_49d1f9fe-8cde-4829-a33f-d75ebc193443">5.2</a>) 
</li>
<li>Rare cases of serious regurgitant cardiac valvular disease have been reported. (<a href="#LINK_94c24ccf-134d-4dbf-854f-b04d698b7166">5.3</a>) 
</li>
<li>Tolerance to the <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> effect usually develops within a few weeks. If this occurs, phentermine should be discontinued. The recommended dose should not be exceeded. (<a href="#LINK_b5eff829-3056-4eb7-9d60-e7b5a6f0a552">5.4</a>) 
</li>
<li>Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. (<a href="#LINK_c9c4ceb1-6b58-4f8c-9833-4e915e6435d9">5.5</a>) 
</li>
<li>Risk of abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. (<a href="#LINK_21c4ba9b-1b90-4b42-bd0b-e16cddfcfb81">5.6</a>) 
</li>
<li>Concomitant alcohol use may result in an adverse drug reaction. (<a href="#LINK_e5105e71-a9d8-40a8-8ec8-a2be06d64ba6">5.7</a>) 
</li>
<li>Use caution in patients with even mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (risk of increase in blood pressure). (<a href="#LINK_b8d7f309-a9d8-4e8f-80d5-1ec383afa485">5.8</a>) 
</li>
<li>A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (<a href="#LINK_4d41f541-5be8-4c66-8ae3-80d0d145af6b">5.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse events have been reported in the cardiovascular, central nervous, gastrointestinal, allergic, and endocrine systems. (<a href="#LINK_177db35e-4e06-4eee-b8f8-2290587abe2a">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc. at 1-800-325-9994 or FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch</span>.</span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk">
<li>Monoamine oxidase inhibitors: Risk of <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>. (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>, <a href="#LINK_4371dc8d-1dbf-4522-b844-112e482283d2">7.1</a>)
</li>
<li>Alcohol: Consider potential interaction (<a href="#LINK_1389284b-1942-45df-8224-6cce42b65b8f">7.2</a>)
</li>
<li>Insulin and oral hypoglycemics: Requirements may be altered. (<a href="#LINK_6bfada60-b04f-437d-8617-103c4e002f62">7.3</a>)
</li>
<li>Adrenergic neuron blocking drugs: Hypotensive effect may be decreased by phentermine. (<a href="#LINK_99c05195-2544-4dd1-8227-6cc4750cc99b">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk">
<li>Nursing mothers: Discontinue drug or nursing taking into consideration importance of drug to mother. (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>,Â <a href="#LINK_04233cef-65a8-45aa-bc31-b0b1be558456">8.3</a>) 
</li>
<li>Pediatric use: Safety and effectiveness not established. (<a href="#LINK_ca468dcf-e0fc-4db8-bfb4-f113d2a54edc">8.4</a>) 
</li>
<li>Geriatric use: Due to substantial renal excretion, use with caution. (<a href="#LINK_c50cc3b7-e636-4331-986e-76ea2b5da0d4">8.5</a>) 
</li>
<li>Use caution when administering phentermine to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#LINK_d1c78636-a730-4483-b390-a3fad1042ebe">8.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Coadministration with Other Drug Products for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary Pulmonary Hypertension</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular Heart Disease</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Development of Tolerance, Discontinuation in Case of Tolerance</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Risk of Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Usage with Alcohol</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Use in Patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Monoamine Oxidase Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Alcohol</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Insulin and Oral Hypoglycemic Medications</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Adrenergic Neuron Blocking Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Acute Overdosage</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Intoxication</span></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_cefde348-0fb1-4093-b556-4340f81f8038"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Phentermine resin extended-release capsules are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> for patients with an initial body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index â‰¥ 30 kg/m<span class="Sup">2</span>, or â‰¥ 27 kg/m<span class="Sup">2</span> in the presence of other risk factors (e.g., controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>).</p>
<p>Below is a chart of body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) based on various heights and weights.</p>
<p>BMI is calculated by taking the patientâ€™s weight, in kilograms (kg), divided by the patientâ€™s height, in meters (m), squared. Metric conversions are as follows: pounds Ã· 2.2 = kg; inches x 0.0254 = meters.</p>
<table width="70%">
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td align="center" colspan="7" valign="top"><p class="First">BODY <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">MASS</span> INDEX (BMI), kg/m<span class="Sup">2</span><br><span class="Bold">Height (feet, inches)</span>Â </p></td></tr>
<tr>
<td align="center"><p class="First"><span class="Bold">Weight<br></span>(pounds)</p></td>
<td align="center"><p class="First"><span class="Bold">5â€™0â€?</span></p></td>
<td align="center"><p class="First"><span class="Bold">5â€™3â€?</span></p></td>
<td align="center"><p class="First"><span class="Bold">5â€™6â€?</span></p></td>
<td align="center"><p class="First"><span class="Bold">5â€™9â€?</span></p></td>
<td align="center"><p class="First"><span class="Bold">6â€™0â€?</span></p></td>
<td align="center"><p class="First"><span class="Bold">6â€™3â€?</span></p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">140</p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First">27</p></td>
<td align="center" valign="top"><p class="First">25</p></td>
<td align="center" valign="top"><p class="First">23</p></td>
<td align="center" valign="top"><p class="First">21</p></td>
<td align="center" valign="top"><p class="First">19</p></td>
<td align="center" valign="top"><p class="First">18</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">150</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">29</p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First">27</p></td>
<td align="center" valign="top"><p class="First">24</p></td>
<td align="center" valign="top"><p class="First">22</p></td>
<td align="center" valign="top"><p class="First">20</p></td>
<td align="center" valign="top"><p class="First">19</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">160</p></td>
<td align="center" valign="top"><p class="First">31</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">28</p></td>
<td align="center" valign="top"><p class="First">26</p></td>
<td align="center" valign="top"><p class="First">24</p></td>
<td align="center" valign="top"><p class="First">22</p></td>
<td align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">170</p></td>
<td align="center" valign="top"><p class="First">33</p></td>
<td align="center" valign="top"><p class="First">30</p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First">28</p></td>
<td align="center" valign="top"><p class="First">25</p></td>
<td align="center" valign="top"><p class="First">23</p></td>
<td align="center" valign="top"><p class="First">21</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">180</p></td>
<td align="center" valign="top"><p class="First">35</p></td>
<td align="center" valign="top"><p class="First">32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">29</p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First">27</p></td>
<td align="center" valign="top"><p class="First">25</p></td>
<td align="center" valign="top"><p class="First">23</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">190</p></td>
<td align="center" valign="top"><p class="First">37</p></td>
<td align="center" valign="top"><p class="First">34</p></td>
<td align="center" valign="top"><p class="First">31</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">28</p></td>
<td align="center" valign="top"><p class="First">26</p></td>
<td align="center" valign="top"><p class="First">24</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">200</p></td>
<td align="center" valign="top"><p class="First">39</p></td>
<td align="center" valign="top"><p class="First">36</p></td>
<td align="center" valign="top"><p class="First">32</p></td>
<td align="center" valign="top"><p class="First">30</p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First">27</p></td>
<td align="center" valign="top"><p class="First">25</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">210</p></td>
<td align="center" valign="top"><p class="First">41</p></td>
<td align="center" valign="top"><p class="First">37</p></td>
<td align="center" valign="top"><p class="First">34</p></td>
<td align="center" valign="top"><p class="First">31</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">29</p></td>
<td align="center" valign="top"><p class="First">26</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">220</p></td>
<td align="center" valign="top"><p class="First">43</p></td>
<td align="center" valign="top"><p class="First">39</p></td>
<td align="center" valign="top"><p class="First">36</p></td>
<td align="center" valign="top"><p class="First">33</p></td>
<td align="center" valign="top"><p class="First">30</p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First">28</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">230</p></td>
<td align="center" valign="top"><p class="First">45</p></td>
<td align="center" valign="top"><p class="First">41</p></td>
<td align="center" valign="top"><p class="First">37</p></td>
<td align="center" valign="top"><p class="First">34</p></td>
<td align="center" valign="top"><p class="First">31</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">29</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">240</p></td>
<td align="center" valign="top"><p class="First">47</p></td>
<td align="center" valign="top"><p class="First">43</p></td>
<td align="center" valign="top"><p class="First">39</p></td>
<td align="center" valign="top"><p class="First">36</p></td>
<td align="center" valign="top"><p class="First">33</p></td>
<td align="center" valign="top"><p class="First">30</p></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First">250</p></td>
<td align="center" valign="top"><p class="First">49</p></td>
<td align="center" valign="top"><p class="First">44</p></td>
<td align="center" valign="top"><p class="First">40</p></td>
<td align="center" valign="top"><p class="First">37</p></td>
<td align="center" valign="top"><p class="First">34</p></td>
<td align="center" valign="top"><p class="First">31</p></td>
</tr>
</tbody>
</table>
<p>The limited usefulness of agents of this class, including phentermine, [see <span class="Italics">Clinical Pharmacology (<a href="#LINK_0ebd2f01-fb5b-4903-9a6c-3d2af1055561">12.1</a>, <a href="#LINK_1c3686de-1542-43d0-84fd-3d6fc808da4c">12.2</a>)</span>] should be measured against possible risk factors inherent in their use such as those described below.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_3b285d95-0e26-4926-8692-bf75a350b483"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span></span></p>
<p>One capsule daily, before breakfast or 10-14 hours before retiring. For individuals exhibiting greater drug responsiveness, phentermine resin extended-release capsules, 15 mg, will usually suffice. Phentermine resin extended-release capsules, 30 mg, are recommended for less responsive patients. Phentermine resin extended-release capsules are not recommended for use in pediatric patients under 16 years of age.</p>
<p>Phentermine resin extended-release capsules should be swallowed whole.</p>
<p>Late evening medication should be avoided because of the possibility of resulting <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. </p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_1849b23c-01ae-4fff-ae4e-920a167500b6"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Phentermine Resin Extended-Release Capsules are available in two strengths:</p>
<p>15 mg: Size #3 grey opaque/maize opaque capsules, imprinted with â€œLCIâ€? on the cap and â€œ1398â€? on the body.</p>
<p>30 mg: Size #3 maize/maize capsules, imprinted with â€œLCIâ€? on the cap and â€œ1366â€? on the body.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_76eb5ea2-968b-4afe-afe8-cffe09885627"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul class="Disk">
<li>History of cardiovascular disease (e.g., <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>) 
</li>
<li>During or within 14 days following the administration of monoamine oxidase inhibitors 
</li>
<li><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> states 
</li>
<li>History of drug abuse 
</li>
<li>Pregnancy [see <span class="Italics">Use in Specific Populations </span><span class="Italics">(<a href="#LINK_6d464131-5469-4ec2-b81a-7aed93eb0059">8.1</a>)</span>] 
</li>
<li>Nursing [see <span class="Italics">Use in Specific Populations </span><span class="Italics">(<a href="#LINK_04233cef-65a8-45aa-bc31-b0b1be558456">8.3</a>)</span>] 
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, or idiosyncrasy to the sympathomimetic amines</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_81abe2cc-cfec-4c7f-9636-a395dae22598"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0d8b1c7d-ac0d-4d15-9645-6889ba4b77cb"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Coadministration with Other Drug Products for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span></h2>
<p class="First"><span class="Bold">Phentermine resin extended-release capsules are indicated only as short-term (a few weeks) monotherapy for the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>. The safety and efficacy of combination therapy with phentermine and any other drug products for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_49d1f9fe-8cde-4829-a33f-d75ebc193443"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary Pulmonary Hypertension</span></h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary Pulmonary Hypertension</span> (PPH) </span><span class="Bold">- a rare, frequently fatal disease of the lungs - has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. </span>The initial symptom of PPH is usually <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. Other initial symptoms may include <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or lower extremity <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or lower extremity <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and patients should be evaluated for the possible presence of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_94c24ccf-134d-4dbf-854f-b04d698b7166"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular Heart Disease</span></h2>
<p class="First"><span class="Bold">Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span> and the use of phentermine alone cannot be ruled out; there have been rare cases of <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span> in patients who reportedly have taken phentermine alone.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b5eff829-3056-4eb7-9d60-e7b5a6f0a552"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Development of Tolerance, Discontinuation in Case of Tolerance</h2>
<p class="First">When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c9c4ceb1-6b58-4f8c-9833-4e915e6435d9"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks</h2>
<p class="First">Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_21c4ba9b-1b90-4b42-bd0b-e16cddfcfb81"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Risk of Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Phentermine is related chemically and pharmacologically to amphetamine (d- and d/l-amphetamine) and other related stimulant drugs that have been extensively abused. The possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. See <span class="Italics">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#LINK_9cb996e8-b698-4049-9c7d-dbfcd24d75ae">9</a>)</span> and <span class="Italics">Overdosage (<a href="#LINK_1f8c485a-a867-463d-8a39-67a7a7cb632d">10</a>)</span>.</p>
<p>The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e5105e71-a9d8-40a8-8ec8-a2be06d64ba6"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Usage with Alcohol</h2>
<p class="First">Concomitant use of alcohol with phentermine may result in an adverse drug reaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b8d7f309-a9d8-4e8f-80d5-1ec383afa485"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Use in Patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Use caution in prescribing phentermine for patients with even mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (risk of increase in blood pressure).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4d41f541-5be8-4c66-8ae3-80d0d145af6b"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">A reduction in insulin or oral hypoglycemic medications in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus may be required.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_177db35e-4e06-4eee-b8f8-2290587abe2a"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described, or described in greater detail, in other sections:</p>
<p>- <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary pulmonary hypertension</span> [see <span class="Italics">Warnings and Precautions (<a href="#LINK_49d1f9fe-8cde-4829-a33f-d75ebc193443">5.2</a>)</span>]</p>
<p>- <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular heart disease</span> [see <span class="Italics">Warnings and Precautions (<a href="#LINK_94c24ccf-134d-4dbf-854f-b04d698b7166">5.3</a>)</span>]</p>
<p>- Effect on the ability to engage in potentially hazardous tasks [see <span class="Italics">Warnings and Precautions (<a href="#LINK_c9c4ceb1-6b58-4f8c-9833-4e915e6435d9">5.5</a>)</span>]</p>
<p>- Withdrawal effects following prolonged high dosage administration [see <span class="Italics">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#LINK_e8d8caab-d763-4445-abb5-7915482aafd7">9.3</a>)</span>]</p>
<p>The following adverse reactions to phentermine have been identified:</p>
<p><span class="Underline">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Primary pulmonary hypertension</span> and/or regurgitant cardiac valvular disease, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, elevation of blood pressure, ischemic events.</p>
<p><span class="Underline">Central </span><span class="Underline">Ner</span><span class="Underline">vous </span><span class="Underline">System</span></p>
<p>Overstimulation, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
<p><span class="Underline">Gastrointestinal</span></p>
<p>Dryness of the mouth, unpleasant taste, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, other <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>.</p>
<p><span class="Underline">Allergic</span></p>
<p><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>.</p>
<p><span class="Underline">Endocrine</span></p>
<p><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, changes in libido.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_d51ec883-35cf-4d79-a5e3-c5fdddb85598"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4371dc8d-1dbf-4522-b844-112e482283d2"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Monoamine Oxidase Inhibitors</h2>
<p class="First">Use of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1389284b-1942-45df-8224-6cce42b65b8f"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Alcohol</h2>
<p class="First">Concomitant use of alcohol with phentermine may result in an adverse drug reaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6bfada60-b04f-437d-8617-103c4e002f62"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Insulin and Oral Hypoglycemic Medications</h2>
<p class="First">Requirements may be altered [see <span class="Italics">Warnings and Precautions (<a href="#LINK_4d41f541-5be8-4c66-8ae3-80d0d145af6b">5.9</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_99c05195-2544-4dd1-8227-6cc4750cc99b"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Adrenergic Neuron Blocking Drugs</h2>
<p class="First">Phentermine may decrease the hypotensive effect of adrenergic neuron blocking drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_2db862a6-f3f4-4559-bffc-c3f1c79960d8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_6d464131-5469-4ec2-b81a-7aed93eb0059"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category X</span></p>
<p>Phentermine is contraindicated during pregnancy because <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and no <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, is currently recommended for all pregnant women, including those who are already overweight or obese, due to obligatory <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> that occurs in maternal tissues during pregnancy. Phentermine has pharmacologic activity similar to amphetamine (d- and d/l-amphetamine) [see <span class="Italics">Clinical Pharmacology (<a href="#LINK_0ebd2f01-fb5b-4903-9a6c-3d2af1055561">12.1</a>)</span>]. Animal reproduction studies have not been conducted with phentermine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_04233cef-65a8-45aa-bc31-b0b1be558456"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if phentermine is excreted in human milk; however, other amphetamines are present in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_ca468dcf-e0fc-4db8-bfb4-f113d2a54edc"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Because pediatric <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is a chronic condition requiring long-term treatment, the use of this product, approved for short-term therapy, is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_c50cc3b7-e636-4331-986e-76ea2b5da0d4"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d1c78636-a730-4483-b390-a3fad1042ebe"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Phentermine was not studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Based on the reported excretion of phentermine in urine, exposure increases can be expected in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Use caution when administering phentermine to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics">Clinical Pharmacology (<a href="#LINK_60cdc50a-f929-400e-8f7e-a1402695cc88">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_9cb996e8-b698-4049-9c7d-dbfcd24d75ae"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e4572c59-87fc-462c-8457-a2d20ae077b1"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Phentermine is a Schedule IV controlled substance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_07c76f5e-a1dc-48c3-9c96-ab7ce5a54a57"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e8d8caab-d763-4445-abb5-7915482aafd7"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Abuse of amphetamines and related drugs may be associated with intense psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times than recommended. Abrupt cessation following prolonged high dosage administration results in extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; changes are also noted on the sleep EEG. Manifestations of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs include severe dermatoses, marked <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>. A severe manifestation of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, often clinically indistinguishable from <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_1f8c485a-a867-463d-8a39-67a7a7cb632d"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3f766009-ea24-4206-813c-ee805df77a96"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Acute Overdosage</h2>
<p class="First">Manifestations of acute overdosage include <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, rapid respiration, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, assaultiveness, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and panic states. <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> usually follow the central stimulation. Cardiovascular effects include <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>. <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. Overdosage of pharmacologically similar compounds has resulted in fatal <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> usually terminates in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<p>Management of acute phentermine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine<span class="Sup">Â®</span>, CIBA) has been suggested on pharmacologic grounds for possible acute, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, if this complicates overdosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a0838955-33f9-4e01-a4db-3ba1ae686e47"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Intoxication</span></h2>
<p class="First">Manifestations of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs include severe dermatoses, marked <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>. The most severe manifestation of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxications</span> is <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, often clinically indistinguishable from <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. See <span class="Italics">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#LINK_e8d8caab-d763-4445-abb5-7915482aafd7">9.3</a>)</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_265f6b5b-0f4c-462a-af14-b04c4ee6fc75"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Phentermine Resin Extended-Release Capsules contain 15 mg and 30 mg respectively of phentermine as the cationic exchange resin complex. Phentermine is Î±, Î±-dimethyl phenethylamine (phenyl-tertiarybutylamine).</p>
<p>Inactive Ingredients: dibasic calcium phosphate, talc, and magnesium stearate. The 15 mg capsule shell consists of D&amp;C Yellow No. 10, FD&amp;C Yellow No. 6, titanium dioxide, gelatin, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, FDA /E172 black iron oxide. The capsule imprinting ink consists of shellac glaze in ethanol, black iron oxide, N-butyl alcohol, propylene glycol, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, D&amp;C Yellow No. 10 Aluminum Lake, ethanol and methanol. The 30 mg capsule shell consists of D&amp;C Yellow No. 10, FD&amp;C Yellow No. 6, titanium dioxide, and gelatin. The capsule imprinting ink consists of shellac glaze in ethanol, black iron oxide, N-butyl alcohol, propylene glycol, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, D&amp;C Yellow No. 10 Aluminum Lake, ethanol and methanol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_3dc87345-2e30-4ed5-8236-ad920b27b204"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_0ebd2f01-fb5b-4903-9a6c-3d2af1055561"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, amphetamine (d- and d/l-amphetamine). Drugs of this class used in <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> are commonly known as "<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectics</span>" or "anorexigenics." It has not been established that the primary action of such drugs in treating <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is one of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite suppression</span> since other central nervous system actions, or metabolic effects, may also be involved.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_1c3686de-1542-43d0-84fd-3d6fc808da4c"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Typical of amphetamines include central nervous system stimulation and elevation of blood pressure. <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">Tachyphylaxis</span> and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_60cdc50a-f929-400e-8f7e-a1402695cc88"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Specific </span><span class="Underline">Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Phentermine was not studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62%-85%. Exposure increases can be expected in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Use caution when administering phentermine to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Underline">Drug </span><span class="Underline">Interactions</span></p>
<p>In a single-dose study comparing the exposures after oral administration of a combination capsule of 15 mg phentermine and 92 mg topiramate to the exposures after oral administration of a 15 mg phentermine capsule or a 92 mg topiramate capsule, there is no significant topiramate exposure change in the presence of phentermine. However in the presence of topiramate, phentermine C<span class="Sub">max</span> and AUC increase 13% and 42%, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_594dee29-26d2-43a4-8ddc-23a50f3cc397"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_c7f7c976-39f4-48b4-97a2-273bd8c5a616"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies have not been performed with phentermine to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_f7603689-7ead-4668-8251-3371515b5c8d"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In relatively short-term clinical trials, adult obese subjects instructed in dietary management and treated with "<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span>" drugs lost more weight on the average than those treated with placebo and diet.</p>
<p>The magnitude of increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> due to the various drug effects are not established. The amount of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> associated with the use of an "<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span>" drug varies from trial to trial, and the increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
<p>The natural history of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is measured over several years, whereas the studies cited are restricted to a few weeks' duration; thus, the total impact of drug-induced <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> over that of diet alone must be considered clinically limited.</p>
<p>The bioavailability of phentermine resin extended-release capsules has been studied in humans in which blood levels of phentermine were measured by a gas chromatography method. Blood levels obtained with the 15 mg and 30 mg resin complex formulations indicated slower absorption with a reduced but prolonged peak concentration and without a significant difference in prolongation of blood levels when compared with the same doses of phentermine hydrochloride. The clinical significance of these differences is not known. In clinical trials establishing the efficacy of phentermine resin extended-release capsules, a single daily dose produced an effect comparable to that produced by other regimens of â€œanorecticâ€? drug therapy.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_525d078e-0e8c-4fc2-9a44-0464a6fed312"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Phentermine Resin Extended-Release Capsules are available in two strengths:</p>
<p>15 mg: Size #3 grey opaque/maize opaque capsules, imprinted with â€œLCIâ€? on the cap and â€œ1398â€? on the body, in bottles of 100 capsules (NDC 0527-1398-01).</p>
<p>30 mg: Size #3 maize/maize capsules, imprinted with â€œLCIâ€? on the cap and â€œ1366â€? on the body, in bottles of 100 capsules (NDC 0527-1366-01).</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, well-closed container as defined in the USP, with a child-resistant closure (as required).</p>
<p>Keep out of the reach of children.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_165bdc1b-1d08-4397-adf0-5f11d699d957"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients must be informed that phentermine is a <span class="Italics">short-term</span> (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and that coadministration of phentermine with other drugs for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> is not recommended [see <span class="Italics">Indications and Usage (<a href="#LINK_cefde348-0fb1-4093-b556-4340f81f8038">1</a>)</span> and <span class="Italics">Warnings and Precautions (<a href="#LINK_0d8b1c7d-ac0d-4d15-9645-6889ba4b77cb">5.1</a>)</span>].</p>
<p>Patients must be instructed on how much phentermine to take, and when and how to take it [see <span class="Italics">Dosage and Administration (<a href="#LINK_1849b23c-01ae-4fff-ae4e-920a167500b6">3</a>)</span>].</p>
<p>Advise pregnant women and nursing mothers not to use phentermine [see <span class="Italics">Use in Specific Populations (<a href="#LINK_6d464131-5469-4ec2-b81a-7aed93eb0059">8.1</a>, <a href="#LINK_04233cef-65a8-45aa-bc31-b0b1be558456">8.3</a>)</span>].</p>
<p>Patients must be informed about the risks of use of phentermine (including the risks discussed in Warnings and Precautions), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action. The risks include, but are not limited to:</p>
<ul class="Disk">
<li>Development of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">primary pulmonary hypertension</span> [see <span class="Italics">Warnings and Precautions (<a href="#LINK_49d1f9fe-8cde-4829-a33f-d75ebc193443">5.2</a>)</span>]</li>
<li>Development of serious <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span> [see <span class="Italics">Warnings and Precautions (<a href="#LINK_94c24ccf-134d-4dbf-854f-b04d698b7166">5.3</a>)</span>]</li>
<li>Effects on the ability to engage in potentially hazardous tasks [see <span class="Italics">Warnings and Precautions (<a href="#LINK_c9c4ceb1-6b58-4f8c-9833-4e915e6435d9">5.5</a>)</span>]</li>
<li>The risk of an increase in blood pressure [see <span class="Italics">Warnings and Precautions (<a href="#LINK_b8d7f309-a9d8-4e8f-80d5-1ec383afa485">5.8</a>)</span> and <span class="Italics">Adverse Reactions (<a href="#LINK_177db35e-4e06-4eee-b8f8-2290587abe2a">6</a>)</span>]</li>
<li>The risk of interactions [see <span class="Italics">Contraindications (<a href="#LINK_76eb5ea2-968b-4afe-afe8-cffe09885627">4</a>)</span>, <span class="Italics">Warnings and Precautions (<a href="#LINK_e5105e71-a9d8-40a8-8ec8-a2be06d64ba6">5.7</a>, <a href="#LINK_4d41f541-5be8-4c66-8ae3-80d0d145af6b">5.9</a>)</span> and <span class="Italics">Drug Interactions (<a href="#LINK_d51ec883-35cf-4d79-a5e3-c5fdddb85598">7</a>)</span>]</li>
</ul>
<p>See also, for example, <span class="Italics">Adverse Reactions (<a href="#LINK_177db35e-4e06-4eee-b8f8-2290587abe2a">6</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#LINK_2db862a6-f3f4-4559-bffc-c3f1c79960d8">8</a>)</span>.</p>
<p>The patients must also be informed about</p>
<ul class="Disk">
<li>the potential for developing tolerance and actions if they suspect development of tolerance [see <span class="Italics">Warnings and Precautions (<a href="#LINK_b5eff829-3056-4eb7-9d60-e7b5a6f0a552">5.4</a>)</span>] and</li>
<li>the risk of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and the potential consequences of abuse [see <span class="Italics">Warnings and Precautions (<a href="#LINK_21c4ba9b-1b90-4b42-bd0b-e16cddfcfb81">5.6</a>)</span>, <span class="Italics">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#LINK_9cb996e8-b698-4049-9c7d-dbfcd24d75ae">9</a>)</span>, and <span class="Italics">Overdosage (<a href="#LINK_1f8c485a-a867-463d-8a39-67a7a7cb632d">10</a>)</span>].</li>
</ul>
<p>Tell patients to keep phentermine in a safe place to prevent <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, misuse or abuse. Selling or giving away phentermine may harm others and is against the law.</p>
<p>Manufactured by:<br><span class="Bold">LANNETT</span><span class="Bold"> COMPANY, INC.</span><br>Philadelphia, PA 19136<br>Made in the USA</p>
<p>Revised 01/2013, Revision 2</p>
<p>10-001</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_e3fbab53-f843-4f23-b52c-fc7250810da3"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 15 mg</h1>
<p class="First"><span class="Bold">NDC 0527-1398-01</span></p>
<p><span class="Bold">Lannett</span></p>
<p><span class="Bold">PHENTERMINE RESINÂ Â Â Â  CIV<br>EXTENDED-RELEASE<br>CAPSULES</span></p>
<p><span class="Bold">15 mg*</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">100 CAPSULES</span></p>
<div class="Figure">
<img alt="phentermine-resin-cap-15mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7ca86c66-409b-4852-8631-c3ada6e60738&amp;name=phentermine-resin-capsules-1.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_fc61e2c0-70cc-4252-a6a5-cb8d43344497"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 30 mg</h1>
<p class="First"><span class="Bold">NDC 0527-1366-01</span></p>
<p><span class="Bold">Lannett</span></p>
<p><span class="Bold">PHENTERMINE RESINÂ Â Â Â  CIV<br>EXTENDED-RELEASE<br>CAPSULES</span></p>
<p><span class="Bold">30Â mg*</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">100 CAPSULES</span></p>
<div class="Figure">
<img alt="phentermine-resin-capsule-30mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7ca86c66-409b-4852-8631-c3ada6e60738&amp;name=phentermine-resin-capsules-2.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENTERMINE RESINÂ 		
					ER</strong><br><span class="contentTableReg">phentermine resin capsule, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0527-1398</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENTERMINE</strong> (PHENTERMINE) </td>
<td class="formItem">PHENTERMINE</td>
<td class="formItem">15Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GRAY,Â YELLOW (gray opaque/maize opaque capsules) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LCI;1398</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0527-1398-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040872</td>
<td class="formItem">07/28/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENTERMINE RESINÂ 		
					ER</strong><br><span class="contentTableReg">phentermine resin capsule, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0527-1366</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENTERMINE</strong> (PHENTERMINE) </td>
<td class="formItem">PHENTERMINE</td>
<td class="formItem">30Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LCI;1366</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0527-1366-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040872</td>
<td class="formItem">07/28/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Lannett Company, Inc.
							(002277481)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lannett Company, Inc.</td>
<td class="formItem"></td>
<td class="formItem">002277481</td>
<td class="formItem">MANUFACTURE(0527-1398, 0527-1366)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lannett Company, Inc.</td>
<td class="formItem"></td>
<td class="formItem">829757603</td>
<td class="formItem">ANALYSIS(0527-1398, 0527-1366), LABEL(0527-1398, 0527-1366), MANUFACTURE(0527-1398, 0527-1366), PACK(0527-1398, 0527-1366)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5adc3ccc-d92b-46dd-b33f-9d3af2f37cb7</div>
<div>Set id: 7ca86c66-409b-4852-8631-c3ada6e60738</div>
<div>Version: 9</div>
<div>Effective Time: 20130131</div>
</div>
</div>Â <div class="DistributorName">Lannett Company, Inc.</div></p>
</body></html>
